Business
Vedanta Presents Expanded Data from Successful Ph1
Vedanta Presents Expanded Data from Successful Ph1.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 5934Z PureTech Health PLC 21 May 2019 \n\n21 May 2019\n \nPureTech Health plc\n \nPureTech Health Affiliate Vedanta Biosciences Announces Expanded Data from Successful Phase 1a/1b Study of VE303 at Digestive Disease Week\n \nExpanded data on rapid, durable, and dose-dependent colonisation of VE303 strains further support optimal dosing regimen and pharmacodynamics of gut microbiota restoration\n \nPhase 2 study of VE303 in recurrent Clostridium difficile infection is ongoing\n \nPureTech Health plc (LSE:PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, is pleased to note that its affiliate Vedanta Biosciences announced the presentation of expanded data from its Phase 1a/1b study of VE303, the Company's lead, orally-administered live biotherapeutic product (LBP) candidate for recurrent Clostridium difficile infection (rCDI). In a milestone for the microbiome field, VE303 data demonstrated that Vedanta's product candidate, composed of a defined bacterial consortium, administered as a standardised lyophilized powder in capsule form, induced rapid, durable and dose-dependent colonisation of VE303 strains. The data were presented at Digestive Disease Week 2019, the world's largest gathering of physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery, held in San Diego, California.\n \nVE303 is currently being evaluated in a Phase 2 study designed to evaluate the safety and efficacy of two different dosages in patients with rCDI. The data from the presentation support the dosing regimen selected for this study and further validate the Company's rationally-defined consortia approach.\n \nThe full text announcement from Vedanta Biosciences is as follows:\n \nVedanta Biosciences Presents Positive Expanded Data from Phase 1a/1b Study of VE303 at Digestive Disease Week\n \nExpanded data on rapid, durable, and dose-dependent colonisation of VE303 strains further support optimal dosing regimen and pharmacodynamics of gut microbiota restoration\n \nPhase 2 study of VE303 in recurrent Clostridium difficile infection is ongoing\n \nCAMBRIDGE, Mass., May 20, 2019 - Vedanta Biosciences, a clinical-stag...